Learnings from over 25 years of PNH experience: The era of targeted complement inhibition

Blood Reviews

Volumn 27, Issue S1, 2013, Pages S1-

  Heitlinger, Ellen ^a  

^a NONE   (Switzerland)

Author keywords

Chronic uncontrolled complement activation; Eculizumab; Nitric oxide scavenging; Paroxysmal nocturnal haemoglobinuria (PNH); Premature mortality; Thrombosis

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOPHOSPHAMIDE; DECAY ACCELERATING FACTOR; ECULIZUMAB; LACTATE DEHYDROGENASE; NITRIC OXIDE; RITUXIMAB; STEROID;

ANTICOAGULANT THERAPY; APLASTIC ANEMIA; ARTICLE; BLOOD TRANSFUSION; BUDD CHIARI SYNDROME; CHRONIC KIDNEY DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; FLOW CYTOMETRY; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HIGH RISK PATIENT; HUMAN; INTRAVASCULAR HEMOLYSIS; MENINGOCOCCOSIS; NEISSERIACEAE INFECTION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; SPLENECTOMY; THROMBOSIS;

CHRONIC UNCONTROLLED COMPLEMENT ACTIVATION; ECULIZUMAB; NITRIC OXIDE SCAVENGING; PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH); PREMATURE MORTALITY; THROMBOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; HUMANS; MOLECULAR TARGETED THERAPY; THROMBOSIS;

EID: 84891906802     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/S0268-960X(13)00080-5     Document Type: Article

References (33)

1. de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008, 112:3099-3106.
2. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995, 333:1253-1258.
3. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005, 106:3699-3709.
4. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011, 117(25):6786-6792.
5. Muus P, Szer J, Schrezenmeier H, Brodsky RA, Bessler M, Socie G, et al. Evaluation of paroxysmal nocturnal hemoglobinuria disease burden: the patient's perspective. A report from the International PNH Registry. Blood 2010, 116:1525. [abstract].
6. Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol 2013, 97(6):749-757.
7. Brodsky RA Paroxysmal nocturnal hemoglobinuria. Hematology: Basic Principles and Practice 2005, 419-427. Elsevier Churchill Livingstone, Philadelphia, PA. 4th ed. R. Hoffman, E.J. Benz, S.J. Shattil (Eds.).
8. Rosse WF Paroxysmal nocturnal hemoglobinuria. Hematology: Basic Principles and Practice 2000, 331-342. Churchill Livingstone, New York, NY. 3rd ed. R. Hoffman, E.J. Benz, S.J. Shattil (Eds.).
9. Brodsky RA Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev 2008, 22(2):65-74.
10. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008, 111:1840-111:1.
11. de Latour RP, Schrezenmeier H, Mary J-Y, Bacigalupo A, de Souza C, Willemze R, et al. Stem cell transplantation for paroxysmal nocturnal haemoglobinuria: an ongoing joint study of the AAWP EBMT Group and the French Society of Haematology. (Abstract). Bone Marrow Transplantation 2009, 43:S57-S58.
12. Hill A, Rother RP, Wang X, Morris SM, Quinn-Senger K, Kelly R, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2010, 149:414-425.
13. Hill A, Kelly RJ, Hillmen P Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013, 121(25):4985-4996.
14. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004, 350:552-559.
15. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muss P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006, 355:1233-355:1.
16. Hillmen P, Muus P, Dührsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007, 110(12):4123-4128.
17. Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2010, 85(8):553-559.
18. Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013, 162(1):62-73.
19. Rother RP, Bell L, Hillmen P, Gladwin MT The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005, 293:1653-1662.
20. Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 2004, 833:193-207.
21. Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993, 73:703ll-70319.
22. Kelly R, Richards S, Hillmen P, Hill A The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag 2009, 5:911-921.
23. Parker CJ Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 2012, 19:141-148.
24. Socie G, Mary J-Y, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet 1996, 348:573.
25. Hill A, Richards S, Hillmen P Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2007, 137:181-192.
26. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
27. Hill A, Sapsford RJ, Scally A, Kelly R, Richards SJ, Khurisgara G, et al. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. Br J Haematol 2012, 158(3):409-414.
28. Hill A, Rother RP, Hillmen P Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Haematologica 2005, 90:40.
29. Richards SJ, Barnett D The role of flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria in the clinical laboratory. Clin Lab Med 2007, 27(3):577-590.
30. Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 2010, 78:211-230.
31. Movalia MK, Weitz IC, Lim SH, Illingworth AJ. Incidence of PNH clones by diagnostic code utilizing high sensitivity flow cytometry. Blood (Abstracts From the 2011 American Society of Hematology Annual Meeting). 2011;118: Abstract 1033.
32. Eculizumab Product Monograph: Alexion Europe SAS, 2012.
33. Meri S Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Int Med 2013, 24(6):496-502.